Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Operating margin grew by 5% over the third quarter of 2023, primarily due to slight revenue growth and cost alignment changes implemented during the second half of 2023 |
| Our recent win in Advocate Health, now our largest client, emphasized our ability to win a broad-based experience RFP that aligned with insights from customers, patients and employee experiences |
| In summary, we believe NRC is well positioned in the market with the right team and strategy to drive meaningful growth and value |
| Our operating margin has improved throughout the year |
| As an opening matter, I'd say the past few quarters have been relatively flat from a top and bottom line perspective, but a lot has been going on behind the scenes, and we're very excited about the base we're building and the direction of our strategic plan |
| We've achieved sequential operating margin expansion over the past three quarters |
| We have a really strong team in place, so you should have a very smooth transition |
| As our plan matures beyond 2024, our goal is to produce double-digit revenue growth and expanded margins |
| Return on average equity improved to 51% in 2023 from 40% in 2022, primarily resulting from returning capital to stockholders through dividends and stock repurchases |
| From a productivity standpoint, our revenue per FTE was up 10% this year over last year |
| Our customer NPS, or Net Promoter Score, hit 75 in the last quarter, which is our highest ever and notable among the world's most respected brands |
| Diluted earnings per share have increased for each quarter in 2023 from expanded operating margins and lower share counts attributable to share repurchases |
| National Research Corporation has achieved significant milestones against each of these goals |
| Key principles of our plan include: doubling our total addressable market across market insights, patient experience, customer experience, and employee experience solutions, being essential to our clients' success by combining our unparalleled healthcare DNA and frontline coaching with innovative new technologies to deliver solutions with return on investment, helping more patients and healthcare providers by aggressively ramping up our sales efforts to gain market share, improving our associates' careers by automating routine tasks and focusing them on their most rewarding and productive activities and delivering more to stockholders through growth, margin expansion and returning excess capital |
| For 2024, from a business perspective, our goals include: number one, expanding our total addressable market to serve customer needs across the experience continuum as they seek to constantly improve their strategies and execution relative to customer service, care delivery and employee satisfaction; number two, using technology, including AI, to regularly launch innovative products that generate return on investment for our customers through new customer acquisition, patient loyalty, reimbursement rates, retention and other outcomes; number three, accelerating sales pipeline growth and conversion; and number four, expanding efficiency and automation throughout our business to minimize [Audio Dip] our associates' talents to create more opportunity |
| Our sales pipeline exceeds $100 million, and recurring new sales were up 18% in the fourth quarter of 2023 compared with the fourth quarter of 2022 |
| Year-to-date, recurring new sales for 2023 grew 24%, or $3 million, over 2022 |
| $55 million in dividends and stock repurchases were returned to stockholders in 2023, helping boost return on equity to 51% and we've distributed another $18 million to stockholders in January of 2024 |
| We have expanded our employee experience and consumer experience capabilities |
| Since mid-2022, the sales team has grown by over 20%, while at the same time, overall associate headcount has been reduced by 16% |
| Looking ahead, our outlook only gets better |
| Metrics are important, but success in the market is the real test |
| The chart posted on our website shows the growth of core revenue and reduction in non-core revenue over the past few years, which is largely complete now |
| Several quarters ago, we reset our strategy to address client demand for expanded market coverage, value-added solutions and greater strategic impact |
| Thank you |
| Diluted earnings per share increased to $0.36 in the fourth quarter of 2023 compared to $0.27 in 2022 and decreased to $1.25 for the year ended 2023 compared to $1.27 in 2022 |
| Statement |
|---|
| Despite the sequential improvement, operating income decreased by 4% and 14% for the fourth quarter and year ended 2023 compared to 2022, respectively |
| From a revenue perspective, our total revenue decreased slightly for both the fourth quarter and year ended 2023 compared to 2022 |
| Our TRCV has declined primarily due to our focus on our core digital solutions and lower net sales, although that trend did improve later in 2023 |
| Higher technology, sales and executive expenses will weigh on sequential margin performance until our expanded product suite and sales pipeline convert to revenue, which is expected to be later in the year |
| This was primarily due to the lack of revenue growth combined with investments in marketing expenses to expand brand recognition and support sales development, technology investments and higher data collection expenses |
| New sales were offset by a reduction in non-core revenue and slightly higher non-renewals |
Please consider a small donation if you think this website provides you with relevant information